|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Russo P: Renal cell carcinoma:
Presentation, staging, and surgical treatment. Semin Oncol.
27:160–176. 2000.PubMed/NCBI
|
|
3
|
Liu L, Zhang W, Qi X, Li H, Yu J, Wei S,
Hao X and Ren X: Randomized study of autologous cytokine induced
killer cell immunotherapy in metastatic renal carcinoma. Clin
Cancer Res. 18:1751–1759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jonasch E and Motzer RJ: Ten years of
progress in renal cell carcinoma. J Natl Compr Canc Netw.
10:690–693. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barata PC and Rini BI: Treatment of renal
cell carcinoma: Current status and future directions. CA Cancer J
Clin. 67:507–524. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bedke J, Gauler T, Grünwald V, Hegele A,
Herrmann E, Hinz S, Janssen J, Schmitz S, Schostak M, Tesch H, et
al: Systemic therapy in metastatic renal cell carcinoma. World J
Urol. 35:179–188. 2017. View Article : Google Scholar :
|
|
7
|
Vachhani P and George S: VEGF inhibitors
in renal cell carcinoma. Clin Adv Hematol Oncol. 14:1016–1028.
2016.
|
|
8
|
Posadas EM, Limvorasak S and Figlin RA:
Targeted therapies for renal cell carcinoma. Nat Rev Nephrol.
13:496–511. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rini BI and Atkins MB: Resistance to
targeted therapy in renal cell carcinoma. Lancet Oncol.
10:992–1000. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Haddad AQ and Margulis V: Tumour and
patient factors in renal cell carcinoma towards personalized
therapy. Nat Rev Urol. 12:253–262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsieh JJ, Manley BJ, Khan N, Gao J, Carlo
MI and Cheng EH: Overcome tumor heterogeneity imposed therapeutic
barriers through convergent genomic biomarker discovery: A braided
cancer river model of kidney cancer. Semin Cell Dev Biol.
64:98–106. 2017. View Article : Google Scholar
|
|
12
|
Tan KB, Harrop J, Reddy M, Young P,
Terrett J, Emery J, Moore G and Truneh A: Characterization of a
novel TNF like ligand and recently described TNF ligand and TNF
receptor superfamily genes and their constitutive and inducible
expression in hemato poietic and non hematopoietic cells. Gene.
204:35–46. 1997. View Article : Google Scholar
|
|
13
|
Zhai Y, Yu J, Iruela-Arispe L, Huang WQ,
Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME, et al:
Inhibition of angio genesis and breast cancer xenograft tumor
growth by VEGI, a novel cytokine of the TNF superfamily. Int J
Cancer. 82:131–136. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chew LJ, Pan H, Yu J, Tian S, Huang WQ,
Zhang JY, Pang S and Li LY: A novel secreted splice variant of
vascular endothelial cell growth inhibitor. FASEB J. 16:742–744.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang N, Sanders AJ, Ye L and Jiang WG:
Vascular endothelial growth inhibitor in human cancer (Review). Int
J Mol Med. 24:3–8. 2009.PubMed/NCBI
|
|
16
|
Zhai Y, Ni J, Jiang GW, Lu J, Xing L,
Lincoln C, Carter KC, Janat F, Kozak D, Xu S, et al: VEGI, a novel
cytokine of the tumor necrosis factor family, is an angiogenesis
inhibitor that suppresses the growth of colon carcinomas in vivo.
FASEB J. 13:181–189. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liang PH, Tian F, Lu Y, Duan B, Stolz DB
and Li LY: Vascular endothelial growth inhibitor (VEGI; TNFSF15)
inhibits bone marrow derived endothelial progenitor cell
incorporation into Lewis lung carcinoma tumors. Angiogenesis.
14:61–68. 2011. View Article : Google Scholar
|
|
18
|
Parr C, Gan CH, Watkins G and Jiang WG:
Reduced vascular endothelial growth inhibitor (VEGI) expression is
associated with poor prognosis in breast cancer patients.
Angiogenesis. 9:73–81. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang N, Sanders AJ, Ye L, Kynaston HG and
Jiang WG: Vascular endothelial growth inhibitor, expression in
human prostate cancer tissue and the impact on adhesion and
migration of prostate cancer cell in vitro. Int J Oncol.
35:1473–1480. 2009.PubMed/NCBI
|
|
20
|
Zhang N, Sanders AJ, Ye L, Kynaston HG and
Jiang WG: Expression of vascular endothelial growth inhibitor
(VEGI) in human urothelial cancer of the bladder and its effects on
the adhesion and migration of bladder cancer cells in vitro.
Anticancer Res. 30:87–95. 2010.PubMed/NCBI
|
|
21
|
Zhang N, Wu P, Shayiremu D, Wu L, Shan H,
Ye L, Zhao X, Cai J, Jiang WG, Gong K, et al: Suppression of renal
cell carcinoma growth in vivo by forced expression of vascular
endothelial growth inhibitor. Int J Oncol. 42:1664–1673. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu L, Li X, Ye L, Shayiremu D, Deng X,
Zhang X, Jiang W, Yang Y, Gong K and Zhang N: Vascular endothelial
growth inhibitor 174 is a negative regulator of aggressiveness and
microvascular density in human clear cell renal cell carcinoma.
Anticancer Res. 34:715–722. 2014.PubMed/NCBI
|
|
23
|
Zhang N, Hong B, Lian W, Zhou C, Chen S,
Du X, Deng X, Duoerkun S, Li Q, Yang Y, et al: Vascular endothelial
growth inhibitor 174 and its functional domains inhibit epithelial
mesen chymal transition in renal cell carcinoma cell in vitro. Int
J Mol Med. 40:569–575. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao Q, Liu T, Hong B, Wang F, Zhou C, Du
X, Chen S, Deng X, Duoerkun S, Li Q, et al: Vascular Endothelial
Growth Inhibitor, a Cytokine of the Tumor Necrosis Factor Family,
is Associated With Epithelial-Mesenchymal Transition in Renal Cell
Carcinoma. Appl Immunohistochem Mol Morphol. 2017. View Article : Google Scholar
|
|
25
|
Szulcek R, Bogaard HJ and van Nieuw
Amerongen GP: Electric cell-substrate impedance sensing for the
quantification of endo thelial proliferation, barrier function, and
motility. J Vis Exp. 85:e513002014.
|
|
26
|
Chen SW, Yang JM, Yang JH, Yang SJ and
Wang JS: A compu tational modeling and analysis in cell biological
dynamics using electric cell-substrate impedance sensing (ECIS).
Biosens Bioelectron. 33:196–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dowling CM, Herranz Ors C and Kiely PA:
Using real time impedance-based assays to monitor the effects of
fibroblast-derived media on the adhesion, proliferation, migration
and invasion of colon cancer cells. Biosci Rep. 34:342014.
View Article : Google Scholar
|
|
28
|
Stefanowicz Hajduk J, Adamska A,
Bartoszewski R and Ochocka JR: Reuse of E plate cell sensor arrays
in the xCEL Ligence Real Time Cell Analyzer. Biotechniques.
61:117–122. 2016. View Article : Google Scholar
|
|
29
|
Kho D, MacDonald C, Johnson R, Unsworth
CP, O'Carroll SJ, du Mez E, Angel CE and Graham ES: Application of
xCEL Ligence RTCA Biosensor Technology for Revealing the Profile
and Window of Drug Responsiveness in Real Time. Biosensors (Basel).
5:199–222. 2015. View Article : Google Scholar
|
|
30
|
Migone TS, Zhang J, Luo X, Zhuang L, Chen
C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, et al: TL1A is a TNF
like ligand for DR3 and TR6/DcR3 and functions as a T cell
costimulator. Immunity. 16:479–492. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tian F, Grimaldo S, Fujita M, Cutts J,
Vujanovic NL and Li LY: The endothelial cell produced
antiangiogenic cytokine vascular endothelial growth inhibitor
induces dendritic cell maturation. J Immunol. 179:3742–3751. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou J, Yang Z, Tsuji T, Gong J, Xie J,
Chen C, Li W, Amar S and Luo Z: LITAF and TNFSF15, two downstream
targets of AMPK, exert inhibitory effects on tumor growth.
Oncogene. 30:1892–1900. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Deng W, Gu X, Lu Y, Gu C, Zheng Y, Zhang
Z, Chen L, Yao Z and Li LY: Down modulation of TNFSF15 in ovarian
cancer by VEGF and MCP 1 is a pre requisite for tumor
neovascularization. Angiogenesis. 15:71–85. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xiao Q, Hsu CY, Chen H, Ma X, Xu J and Lee
JM: Characterization of cis regulatory elements of the vascular
endothelial growth inhibitor gene promoter. Biochem J. 388:913–920.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Haridas V, Shrivastava A, Su J, Yu GL, Ni
J, Liu D, Chen SF, Ni Y, Ruben SM, Gentz R, et al: VEGI, a new
member of the TNF family activates nuclear factor kappa B and c Jun
N terminal kinase and modulates cell growth. Oncogene.
18:6496–6504. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hou W, Medynski D, Wu S, Lin X and Li LY:
VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor
vascular endothelial cells and suppresses tumor growth. Clin Cancer
Res. 11:5595–5602. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Meyer CJ, Krauth M, Wick MJ, Shay JW,
Gellert G, De Brabander JK, Northcote PT, Miller JH and Peloruside
A: Peloruside A Inhibits Growth of Human Lung and Breast Tumor
Xenografts in an Athymic nu/nu Mouse Model. Mol Cancer Ther.
14:1816–1823. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang K, Cai HX, Gao S, Yang GL, Deng HT,
Xu GC, Han J, Zhang QZ and Li LY: TNFSF15 suppresses VEGF
production in endothelial cells by stimulating miR 29b expression
via activation of JNK GATA3 signals. Oncotarget. 7:69436–69449.
2016.PubMed/NCBI
|
|
39
|
Qi JW, Qin TT, Xu LX, Zhang K, Yang GL, Li
J, Xiao HY, Zhang ZS and Li LY: TNFSF15 inhibits vasculogenesis by
regu lating relative levels of membrane bound and soluble isoforms
of VEGF receptor 1. Proc Natl Acad Sci USA. 110:13863–13868. 2013.
View Article : Google Scholar
|
